menu search

ALGS / Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company will present seven posters collectively highlighting data on its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023. Read More
Posted: Jun 7 2023, 07:30
Author Name: GlobeNewsWire
Views: 102077

ALGS News  

Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

By GlobeNewsWire
June 7, 2023

Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company fo more_horizontal

Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference

By GlobeNewsWire
May 24, 2023

Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company foc more_horizontal

Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates

By Zacks Investment Research
May 4, 2023

Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compar more_horizontal

Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023

By GlobeNewsWire
April 11, 2023

Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023

SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company f more_horizontal

Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates

By Zacks Investment Research
March 9, 2023

Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates

Aligos Therapeutics, Inc. (ALGS) delivered earnings and revenue surprises of -4.08% and 26.32%, respectively, for the quarter ended December 2022. Do more_horizontal


Search within

Pages Search Results: